Abstract
Several recent publications have shed new light on the role of epigenetic modifications in cancer stem cell (CSC) biology. Among other epigenetic players, polycomb group genes appear to be particularly attractive. Indeed, they are emerging as CSC-specific markers, as well as potential targets for cancer therapy. However, before these discoveries can be applied to the clinical setting, the specific role of polycomb group genes in CSC tumorigenic activity should be explained further.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
